IBS-D
FDA Determines REMS for Alosetron No Longer Necessary
The FDA has determined Risk Evaluation and Mitigation Strategies for the irritable bowel syndrome drug alosetron ...
SEPTEMBER 26, 2023
Tips for Treating Challenge Cases of IBS-D
For patients in whom diarrhea affects quality of life, diet, pharmaceutical agents and behavioral therapy are ...
JUNE 22, 2023
Load more